1.61BMarket Cap
42.76P/E TTM
Key Figures
3.580Open
4.120High
1.72MVolume
42.76P/E TTM
21.58P/E Dynamic
--Dividend TTM
0.55%Turnover Ratio
3.570Prev. Close
3.540Low
5.37MTurnover
LossP/E Static
-7.27P/B
0.00%Div Yield TTM
2.06%ROA
11.85052wk High
1.33Volume Ratio
-231.86MNet Profit
311.72MShares
0.0964EPS TTM
0.22Beta
--ROE
3.03052wk Low
16.25%Amplitude
56.50%Gross Margin
1.61BMarket Cap
0.81Reward/Risk
3.92%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Alvotech SA's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 141 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.50.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Alvotech SA Highlights
StrengthsRisks
Alvotech SA News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Alvotech SA Info
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Ticker SymbolALVO
CompanyAlvotech SA
CEOWessman (Robert)
Websitehttps://www.alvotech.com/
Shareholders
FAQs
What is the current price of Alvotech SA (ALVO)?
The current price of Alvotech SA (ALVO) is 4.12.
What is the symbol of Alvotech SA?
The ticker symbol of Alvotech SA is ALVO.
What is the 52-week high of Alvotech SA?
The 52-week high of Alvotech SA is 11.85.
What is the 52-week low of Alvotech SA?
The 52-week low of Alvotech SA is 3.03.
What is the market capitalization of Alvotech SA?
The market capitalization of Alvotech SA is 1.61B.
Is Alvotech SA (ALVO) currently rated as Buy, Hold, or Sell?
According to analysts, Alvotech SA (ALVO) has an overall rating of Buy, with a price target of 6.50.
What is the Earnings Per Share (EPS TTM) of Alvotech SA (ALVO)?
The Earnings Per Share (EPS TTM) of Alvotech SA (ALVO) is 0.10.
